WWW.NET.KNIGI-X.RU
    -
 

Pages:     | 1 ||

03.01.06 - ...

-- [ 2 ] --

1. , .

2. , , (56882590-17-12 56882590-18-13 ).

3. - , ( 2523948).

6.

1. , , , , . , , .

2. , , , . .



7.

1. .. , / .. // . . . 2002. .

XLVI . 43-51.

2. .., .. / .., .. . ..

.// ( ). .: 1997. .270-296.

3. Goldwasser E. Erythropoietin and differentiation of red blood cells./ Goldwasser E. //Feder. Proc. 1975. vol.34. P. 2285-2292.

4. Jelkmann W. Renal erythropoietin: properties and production./ Jelkmann W. // Rev. Physiol. Biochem. Pharmacol. 1986. vol.104. P.139-217.

5. .. ./ .., . ., .., . ., .., .. . . -, 2010. 631 640 .

6. .. , "biosimilars" (- ). / .., .., .. . // . - 2014. - .49 - 11-22 .

7. Eschbach J.W. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial./ Eschbach J.W., Egrie J.C., Downing M.R. et al. // N. Engl. J. Med. 1987 .

73-78.

8. .. : . / .., .. // . 1990 . 62. .

141-145.

9. .. . / .., .., .. . // .





1991 . 63. . 81-86.

10. .. . / .., .., .. // 1993 . 30-33.

11. Pinevich A.J. Anemia. Dialysis and Transplantation / Pinevich A.J., Petersen J. // West J Med. 1992 vol. 157. P. 154 157.

12. Deicher R. Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease./ Deicher R., Horl W.H. // Drugs. 2004 vol. 64. P. 499-509.

13. .. . / ., .., . . // . 2013 . 47. . 4-11.

14. .. - ( ) . / .. // . 2007 .9 . 216-223.

15. Elliott S. Enhancement of therapeutic protein in vivo activities through glycoengineering. / Elliott S., Lorenzini T., Asher S. et al. // Nat Biotechnol. 2003.

vol. 21 P. 414-421.

16. Sinclair A.M. Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. / Sinclair A.M., Elliott S. // J Pharm Sci. 2005 vol. 94 P. 16261635.

17. Walsh G. Post-translational modifications of protein biopharmaceuticals. / Walsh G. // Drug discovery today. 2010. vol. 15 P. 773-780.

18. Lai P.H. Structural characterization of human erythropoietin/ P.H. Lai, R.

Everett, F.F. Wang et al. // J.Biol.Chem. 1986. vol.261 P. 3116-3121.

19. Takeuchi M. Relationship between sugar chain structure and biological activityof recombinant human erythropoietin produced in Chinese hamster ovary cells / Takeuchi M., Inoue N., Stricland T.W. et al. // Proc. Nati. Acad. Sci. USA. 1989. vol. 86 P. 7819-7822.

20. Gross A.W. Cellular Trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP)/ A.W.Gross, H.F.Lodish // J.Biol.Chem. 2006. vol.281 P.2024-2032.

21. Eric G. Stefanich. Evidence for an asialoglycoprotein receptor on nonparenchymal cells for O-linked glycoproteins. / E. G. Stefanich, S. Ren, D. M.

Danilenko et al. // J. Pharmacology and Exp. Therapeutics. 2008. vol. 327 P.

308-315.

22. Egrie J.C. Development and characterization of novel erythropoiesis stimulating protein (NESP). / Egrie J.C. and Browne J.K. // British J. of Cancer. 2001. vol. 84 P. 3-10.

23. Aminoff D. Role of sialic acid in survival of erythrocytes in the circulation: interaction of neuraminidase-treated and untreated erythrocytes with spleen and liver at the cellular level. / Aminoff D., Bruegge W., Bell W. et al. // Proc. Natl. Acad. Sci. USA. 1977. vol. 74 P. 1521-1524.

24. Morell A. The role of sialic acid in determining the survival of glycoproteins in the circulation. / Morell A.G., Gregoriadis G., Scheinberg I.H. et al.

// J. Biol. Chem. 1971. vol. 246 P. 1461-1467.

25. Knauft M. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers / Knauft M., Bell D.P., Hirtzer P. et al. // J.Biol.Chem. 1988. vol. 263 P. 15064-15070.

26. Briggs D.W. Hepatic clearance of intact and desialylated erythropoietin. / Briggs D.W., Fisher J.W., George W.J. // American J.Physiology. 1974. vol. 227

P. 1385-1388.

27. Vadhan-Raj S. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks.

/ Vadhan-Raj S., Mirtsching B., Charu V. et al. // The J. Of Supp. Oncol. 2003. vol. 1 P. 131-138.

28. Egrie G.C. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. / Egrie G.C., Dwyer E., Browne J.K. et al. // Exp. Hematol. 2003. vol. 31 P. 290-299.

29. Macdougall I.C. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. / Macdougall I.C., Gray S.J., Elston O., et al. // Am Soc Nephrol. 1999. vol. 87 P. 2392-2395

30. Mirtsching B. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis. / Mirtsching B., Charu V., Vadhan-Raj S., et al. // Oncology. 2002. vol. 16 P. 31-36.

31. Elliott S.G., Byrne T.E. Glycosylation analogs of erythropoietin // United States Patent US 7217689 B1. 2007.

32. European Pharmacopoeia Edition 8, 2014. P. 1813.

33. Fisher J.W. Erythropoietin: physiology and pharmacology update. / Fisher J.W. // Exp. Biol. Med. - 2003. - vol. 228 - P. 1-14.

34. Brown J.K. Erythropoietin: gene cloning, protein structure, and biological properties. / Brown J.K., Cohen A.M., Egrie J.C., et al. //Cold Spring Harb Symp Quant. Biol. -1986. vol. 51 P. 693-702.

35. Egrie J.C. Characterization and biological effects of recombinant human erythropoietin. / Egrie J.C., Strickland T. W., Lane J., et al. // Immunobiology 1986. vol. 172 P. 213-224.

36. . . , . / . ., .., .. , 2003. 173 .

37. Santos M.R. Separation of Recombinant Human Erythropoietin (rhEPO) using the European Pharmacopoeia Method on the PA 800 plus Pharmaceutical Analysis System. / Santos M.R. // Beckman Coulter 2012. P. 1-8.

38. Delorme E. Role of glycosylation on the secretion and biological activity of erythropoietin. // Delorme E., Lorenzini T., Giffin J. et al. // Biochemistry 1992.

vol. 31 P. 9871-9876.

39. Robinson D.M. Darbepoetin alfa: its use in anemia associated with chronic kidney disease. / Robinson D.M., Easthope S.E. // BioDrugs 2005. vol. 19 P.

327 343.

40. Lin F.K. Cloning and expression of the human erythropoietin gene. / Lin F.K., Suggs S., Lin C.H. et al. // Proc Natl Acad Sci USA 1985. vol. 82 P.

7580-7584.

41. Jelkman W. The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP. / Jelkman W. // Eur J Haematol. 2002. vol. 69 P. 265-274.

42. Skibeli V. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. / Skibeli V., Nissen-Lie G., Torjesen P. // Blood. 2001. vol. 98 P. 3626-3634.

43. Halstenson C.E. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. / Halstenson C.E., Macres M., Katz S.A. et al. // Clin Pharmacol Ther. 1991. vol. 50 P. 702-712.

44. Stockenhuber F. Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or continuous ambulatory peritoneal dialysis. / Stockenhuber F., Loibl U., Gottsauner-Wolf M. et al. // Nephron. 1991. vol. 59 P. 399-402.

45. Nimtz M. Structures of sialylated oligosaccharides of human erythropoietin expressed in recombinant BHK-21 cells. / Nimtz M., Martin W., Wray V., et al. // Eur J Biochem. 1993. vol. 213 P. 39-56.

46. Macdougall I.C. Novel erythropoiesis stimulating protein. / Macdougall I.C. // Semin. Nephrol. 2000. vol. 20 P. 375-381.

47. Scott S.D. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies. / Scott S.D. // Pharmacotheropy. 2002 vol. 22 P. 160S-165S.

48. Allon M. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis / Allon M., Kleinman K., Walczyk M., et al. // Clin Pharmacol Ther. 2002. vol. 72 P.546-555.

49. .. . / .. // . 2013. .3 70-73 .

50. .. . / .. // . 2011. - 2.

51. .. : . / .. // . 2008. . 16 30 35 .

52. 12.04.10 61- (. 12.03.2014) .

53. Directive 2001/83/EC of the european parliament and of the council of 6 november 2001 on the community code relating to medicinal products for human use: Official journal L 311. 2004. P. 67 128.

54. EU guidelines for generics [ ] // Generics and

Biosimilars initiative. 2010. :

http://www.gabionline.net/Guidelines/EU-guidelines-for-generics/.

55. .. : . / .., .. // :

. 2010. .1 50-54 .

56. Morawala P.V., Sunit M., Sudhir J., Ashutosh V., Gopal D., Srinivas I. A process for recovering darbepoietin alfa isoforms // International application published under the patent cooperation treaty WO 2011/024024 Al. 2011.

57. .., .., .., .., .., .. - , // 2523948 2013.

58. .. CHO, -, . / .., .., .., .., .. . // . 2012. - . 5 - 55-65 .

59. .. - . / .., .., .., .., .., .., .. . // . 2013. .2 .

60. .. , CHO-Epo-2. / .., .., .. . // . 2013. . 4 - 48-55 .

61. . . : / ., . .; . . , . , . .

: . , 1988. - 278 .

62. Riechmann L. Reshaping human antibodies for therapy. / Riechmann L., Clark M., Walmann H. et al. // Nature. - 1988. - vol. 332 - P. 323-327.

63. Ratner B. Allergy, Anaphylaxis and immunotherapy: / Ratner B. - Baltimore: Williams and Wilkins, 1943.

64. Miller R.A. Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. / Miller R.A., Oseroff A.R., Stratte P.T. et al. // Blood. - 1983. vol. 62 - P. 988-995.

65. Lai P.H., Strickland T.W. Erythropoietin purification // United States Patent 4667016. 1987.

66. Egrie J.C. Novel erythropoiesis stimulating protein (NESP) has a longer serum half-life and greater in vivo biological activity than recombinant human erythropoietin (rHuEPO). / Egrie J.C., Dwyer E., Lykos M. et al. // Blood. - 1997. vol.90 - P. 243.

67. Elliott S.G. Rational design of novel erythropoiesis stimulating protein (ARANESP): a super-sialated molecule with increased biological activity. / Elliott S.G., Lorenzini T., Strickland T. et al. // Blood. - 2000. - vol. 96 - P. 352.

68. Macdougall I.C. Pharmacology of darbepoetin alfa. / Macdougall I.C., Padhi D., Jang G. // Nephrol Dial Transplant. - 2007 - vol. 22 - P. iv2iv9.

69. Sasu B.J. Comparison of epoetin alfa and darbepoetin alfa biological activity under different administration schedules in normal mice. / Sasu B.J., Hartley C., Schultz H. et. al. // Acta Haematol. - 2005. - vol. 113 - P. 163Sinclair A. M. Erythropoiesis stimulating agents: approaches to modulate activity. / Sinclair A. M. // Biologics: Targets and Therapy. - 2013. - vol. 7 - P. 161 .. / .. , .. , .. . - : , 1986. - 7.

72. . . : / . - :

, 2009. - 17.

73. .. / .. . - : , 2010. - 11 .

74. : / .., .., .., .., .., .. - . - , 2014. - 188 .

75. .. . / ..

, .. . - : , 1997. 28-30.

76. : / .., .. - :

. .. , 2007 - .63Reichel C. Handbook of Experimental Pharmacology / Reichel C., Gmeiner G. - Seibersdorf: D. Thieme and P. Hemmersbach, 2010. 251-294 P.

78. :

/ .. - : , 2007 .

79. Quality assurance of pharmaceuticals: meting a major public health challenge. The who expert committee on specifications for pharmaceutical preparations / Geneva: WHO, 2013.

80. Validation of analytical procedures: Text and methodology. Q2(R1), ICH WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-second Report. Geneva, World Health Organization, 1992 (WHO Technical Report Series, No. 823).

82. The United States Pharmacopoeia 30 The National Formulary. 1225 Validation of Compendial Procedures, 2008.

83. Guidance for Industry. Process Validation: General Principles and Practices / FDA, CDER, CBER, CVM. - 2011.

84. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. / Laemmli U.K. // Nature. 1970. vol. 227 P. 680 .. [ ] / .., .. // -. 2008. . 48. : http://www.vector-best.ru/nvb/n48/st48_4.htm

86. Instruction for use Quantikine IVD Human Erythropoietin ELISA R&D Systems Inc. Catalog Number DEP00.

87. 26.06.08 102- (. 23.06.2014) " "

88. 5725-6-2002 . ( ) . 6. . : , 2002.

89. Ermer J. Method Validation in Pharmaceutical Analysis: A Guide to Best Practice. / Ermer J., Miller J. - Wiley-VCH Verlag GmbH & Co. KGaA, 2005. P.

243 264.

90. Reviewer Guidance. Validation of Chromatographic Methods. Center for Drug Evaluation and Research (CDER), 1994.

91. Lacunza I. Selection of migration parameters for a highly reliable assignment of bands of isoforms of erythropoietin separated by capillary electrophoresis. / Lacunza I., Lara-Quintanar P., Moya G. et. Al. // Anal. Chem. 2004. vol. 25 P. 1569-1579.

92. Boucher S. Qualitative and quantitative assessment of marketed erythropoiesis-stimulating agents by capillary electrophoresis. / Boucher S., Kane A., Girard M. // Journal of Pharmaceutical and Biomedical Analysis. 2012. vol.

71 P. 207-013.

93. Bietlot H. Analysis of recombinant human erythropoietin in drug formulations by high-performance capillary electrophoresis. / Bietlot H., Girard M. // Journal of Chromatography. 1997. vol. 759 P. 177-184.

94. Gimenez E. Analysis of intact erythropoietin and novel erythropoiesisstimulating protein by capillary electrophoresis-electrosprayion trap mass spectrometry. / Gimenez E., Benavente F., Barbosa J. et al. // Electrophoresis. 2008. vol. 29 P. 2161-2170.

95. Schiestl M. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. / Schiestl M., Stangler T.,Torella C. // Nature biotechnology. 2011. vol. 29 P. 310-312.

96. 8.315-97 . . : , , 1997.

97. Andersen, D.C. Recombinant protein expression for therapeutic applications / D.C. Andersen, L. Krummen // Curr. Opin. Biotechnol. 2002. Vol.

13. P. 117123.

98. Pavlou, A.K. Recombinant protein therapeutics success rates, market trends and values to 2010 / A.K. Pavlou and J.M. Reichert // Nat. Biotechnol. 2004. Vol. 22 P. 15131519.

99. Wurm, F.M. Production of recombinant protein therapeutics in cultivated mammalian cells / F.M. Wurm // Nature Biotechnol. 2004. Vol. 22 P. 1393 1398.



Pages:     | 1 ||
:

Ͳ . . ʲ =========================================================================== 612.017.2 - . . ...

- 13.00.02 () ...

- : (- ) 22.00.01 , ...

" " ( ") .. 16.12.2015 ...

() , - - ...

"-12,12" , , . , , , , . , , ....

1. " " - , . ...

3 (25) 2013. . 88-95. us.chuikov@mail.ru , , ,...

1 2015 . 90 , , , , , ...

" ...








 
<<     |    
2017 www.net.knigi-x.ru - -

, .
, , , , 1-2 .